Bullish
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com
Xenon Pharmaceuticals' azetukalner demonstrated a significant reduction in monthly seizure frequency, with a 53.2% decrease in the 25 mg group during ...